<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=7244&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="157162" class="table-">
                
                <td>Nov. 16, 2021, 6:30 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Groups 1-10: Number of Participants with Adverse Events of Special Interest (AESIs);Groups 1-10: Number of Participants with Serious Adverse Events (SAEs);Groups 1-6: Enzyme-Linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 1;Groups 1-6: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations (GMCs) 28 Days After Vaccination 2;Groups 1-6: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination;Groups 1-6: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 1-6: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 1;Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After Vaccination 2;Groups 1-6: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 1-6: Serological Response to Vaccination as Measured by VNA Titers 28 Days After Vaccination 1;Groups 1-6: Virus Neutralization Assay Geometric Mean Titer 28 Days After Vaccination 1;Groups 1-6: Virus Neutralization Assay Geometric Mean Titer (GMT) 28 Days After Vaccination 2;Groups 7-8: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 2;Groups 7-8: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination;Groups 7-8: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 7-8: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 7-8: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 2;Groups 7-8: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 7-8: Virus Neutralization Assay GMTs 28 Days After Vaccination 2;Groups 9-10: Enzyme-linked Immunosorbent Assay GMCs 28 Days After Vaccination 2;Groups 9-10: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination;Groups 9-10: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 9-10: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 9-10: Serological Response to Vaccination as Measured by ELISA 28 Days After Vaccination 2;Groups 9-10: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 9-10: Virus Neutralization Assay GMTs 28 Days After Vaccination 2;Groups A-C: Number of Participants with AESIs;Groups A-C: Number of Participants with SAEs;Groups A-C: Number of Participants with Solicited Local AEs for 7 Days After Vaccination;Groups A-C: Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination;Groups A-C: Number of Participants with Unsolicited AEs for 28 Days After Vaccination
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Groups 1-10: Number of Participants with Adverse Events of Special Interest (AESIs);Groups 1-10: Number of Participants with Serious Adverse Events (SAEs);Groups 1-6: Enzyme-Linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 1;Groups 1-6: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations (GMCs) 28 Days After Vaccination 2;Groups 1-6: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination;Groups 1-6: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 1-6: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 1;Groups 1-6: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After Vaccination 2;Groups 1-6: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 1-6: Serological Response to Vaccination as Measured by VNA Titers 28 Days After Vaccination 1;Groups 1-6: Virus Neutralization Assay Geometric Mean Titer 28 Days After Vaccination 1;Groups 1-6: Virus Neutralization Assay Geometric Mean Titer (GMT) 28 Days After Vaccination 2;Groups 7-8: Enzyme-linked Immunosorbent Assay Geometric Mean Concentrations 28 Days After Vaccination 2;Groups 7-8: Number of Participants with Solicited Local AEs for 7 Days After Each Vaccination;Groups 7-8: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 7-8: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 7-8: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay 28 Days After Vaccination 2;Groups 7-8: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 7-8: Virus Neutralization Assay GMTs 28 Days After Vaccination 2;Groups 9-10: Enzyme-linked Immunosorbent Assay GMCs 28 Days After Vaccination 2;Groups 9-10: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination;Groups 9-10: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination;Groups 9-10: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination;Groups 9-10: Serological Response to Vaccination as Measured by ELISA 28 Days After Vaccination 2;Groups 9-10: Serological Response to Vaccination as Measured by Virus Neutralization Assay (VNA) Titers 28 Days After Vaccination 2;Groups 9-10: Virus Neutralization Assay GMTs 28 Days After Vaccination 2;Groups A-C: Number of Participants with AESIs;Groups A-C: Number of Participants with SAEs;Groups A-C: Number of Participants with Solicited Local AEs for 7 Days After Vaccination;Groups A-C: Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination;Groups A-C: Number of Participants with Unsolicited AEs for 28 Days After Vaccination
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>